Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders
2024-01-29
寡核苷酸
SUZHOU, China, Jan. 29, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the charge in small activating RNA (saRNA) therapeutics, announces a formal collaboration with University Medical Center Utrecht, affiliated with Utrecht University. This strategic alliance unites their respective strengths to advance the development of saRNA-based treatments for a spectrum of intractable neurodevelopmental disorders.
Professor Bobby Koeleman, Group Leader at the Department of Genetics within the Center for Molecular Medicine at Utrecht University, will lead the collaboration with Ractigen Therapeutics. By synergistically leveraging Ractigen's cutting-edge saRNA discovery platform, medicinal chemistry expertise, and innovative oligonucleotide delivery systems, the partnership aims to translate promising preclinical research into clinically efficacious therapeutics. Professor Koeleman's research team, lauded for their work in elucidating the genetic underpinnings of severe childhood epilepsies, will contribute novel gene targets brimming with therapeutic potential.
This partnership represents a practical approach to integrating academic research with industry capabilities to develop potential treatments for neurodevelopmental disorders. Through this collaboration, Ractigen's technology and Utrecht University's research are expected to contribute significantly to the field of saRNA therapeutics and therapeutic development for neurodevelopmental disorders.
Dr. Long-Cheng Li, CEO of Ractigen Therapeutics, commented on the collaboration: "Our partnership with Utrecht University represents a significant step forward in our mission to develop innovative therapies for challenging genetic disorders. By combining our RNAa technology and advanced delivery systems with Utrecht's impactful research, we believe we can make a real difference in the field of neurodevelopmental disorders."
The University Medical Center Utrecht is one on the biggest public healthcare institutions in the Netherlands. It is affiliated with the Utrecht University. Professor Koeleman is an expert in genetics, dedicated to find genetic causes of both common and rare genetic disease, and subsequently aims to translate the genetic finding to clinical relevance. His group focuses in developing small activating RNAs (saRNAs) for genes associated with severe childhood epilepsies.
About Ractigen Therapeutics
Ractigen Therapeutics is at the forefront of developing saRNA drugs, utilizing the RNAa mechanism to up-regulate endogenous gene expression. This cutting-edge approach harnesses the power of saRNA to specifically target and enhance the transcription of target genes, thereby restoring their normal protein function. By overcoming gene silencing or insufficient protein production through targeted upregulation, Ractigen tackles previously intractable conditions, offering renewed hope to patients and families impacted by a range of complex genetic disorders.
Contact Information:
www.ractigen.com
SOURCE Ractigen Therapeutics
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-药物
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。